IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of...
20 insider purchases on record · latest filing 2026-03-02.
Insiders have also filed 84 sale transactions at IDYA.